Jul 2 |
Ardelyx stock tumbles 20% on CMS payment update
|
Jul 2 |
To Preserve Patient Access to XPHOZAH®, Ardelyx Chooses Not to File for TDAPA
|
Jun 28 |
Ardelyx Presents Additional Data Detailing Educational Needs Related to IBS-C Management Across Healthcare Disciplines
|
Jun 27 |
Ardelyx: Potential Headwinds From Weight-Loss Drug Advancements
|
Jun 22 |
When Will Ardelyx, Inc. (NASDAQ:ARDX) Become Profitable?
|
Jun 16 |
3 Stocks Under $10 With the Potential to Make You a Millionaire
|
May 30 |
Medical Moonshots: 3 Biotech Stocks Set to Skyrocket
|
May 24 |
Ardelyx slips as commercial chief departs
|
May 22 |
Ardelyx to Participate at the 2024 Jefferies Global Healthcare Conference
|
May 21 |
Ardelyx Presents Additional Data at the 2024 Digestive Disease Week Conference on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults
|